Clinical Trial Finder

Inclusion Criteria:

1. Patients must have a full understanding of this study and voluntarily sign an informed consent form; 2. Age ≥ 18 years old and age ≤ 80 years old; 3. Patients with pancreatic neuroendocrine tumors diagnosed by histopathology or cytology, who have progressed after previous treatments such as SSA, targeted therapy, and chemotherapy (all grades of pancreatic neuroendocrine tumors and neuroendocrine cancers are allowed to be included); 4. According to the criteria for evaluating the efficacy of solid tumors (RECIST V1.1), there should be at least one measurable lesion; 5. At least 7 days have passed since the end of the last systemic treatment, and palliative radiotherapy for localized areas is allowed. It has been completed for more than 4 weeks; 6. Expected survival time ≥ 12 weeks; 7. Researchers estimate that patients can benefit from it; 8. The patients have sufficient organ and bone marrow function; 9. Male or female patients with fertility voluntarily use effective contraceptive methods, such as double barrier contraception, condoms, oral or injectable contraceptives, intrauterine devices, etc., during the study period and within 6 months of the last study medication. All female patients will be considered to have fertility unless they have undergone natural menopause, artificial menopause, or sterilization surgery (such as hysterectomy, bilateral adnexectomy, or radiation ovarian irradiation).

Exclusion Criteria:

1. Other malignant tumors have been diagnosed in the past 5 years, except for effectively treated skin basal cell carcinoma, skin squamous cell carcinoma, or effectively resected cervical carcinoma in situ, breast cancer; 2. Simultaneously receiving other investigational drugs or approved or investigational anti-tumor treatments; 3. Patients with contraindications to experimental drugs (such as active bleeding, ulcers, intestinal perforation, intestinal obstruction, uncontrolled hypertension, III-IV grade heart failure, within 30 days after major surgery, severe liver and kidney dysfunction, etc.); 4. The patient currently has any diseases or conditions that affect drug absorption, or the patient is unable to take oral medication; 5. Confirmed allergy to any component of the investigational drug and/or its excipients; 6. Pregnant (positive pregnancy test before medication) or breastfeeding women; 7. Patients with large amounts of pleural effusion or ascites requiring drainage; 8. Any other disease with clinically significant metabolic abnormalities, physical examination abnormalities, or laboratory examination abnormalities. According to the researcher's judgment, it is suspected that the patient has a certain disease or condition that is not suitable for the use of the study drug (such as having seizures and requiring treatment), or that it will affect the interpretation of the study results, or put the patient in a high-risk situation; 9. Have taken medication containing components of Hypericum perforatum within 3 weeks prior to the first study medication. Or have taken other strong inducers or inhibitors of CYP3A4 within the previous 2 weeks; 10. According to the judgment of the investigator, the subject has other factors that may lead to the forced termination of this study or are not suitable for inclusion, such as other serious concomitant diseases (such as severe diabetes, thyroid disease, spinal cord compression, superior vena cava syndrome, mental illness), serious laboratory examination abnormalities, accompanied by family or social factors, which will affect the safety of the subject, or the collection of data and samples).

Neuroendocrine neoplasms (NENs) are heterogeneous tumors originating from peptidogenic neurons and neuroendocrine cells. Most commonly found in the digestive tract or lungs, it can be a benign or malignant tumor. According to their origin, neuroendocrine neoplasms are usually divided into pancreatic neuroendocrine neoplasms and non pancreatic neuroendocrine neoplasms. Approved targeted therapy drugs include sunitinib and everolimus, used to treat pancreatic neuroendocrine neoplasms or highly differentiated non functional gastrointestinal or pulmonary neuroendocrine neoplasms. The gastrointestinal tract and pancreas are home to 12 and 4 types of neuroendocrine cells, respectively, and are the most common sites of NEN occurrence, accounting for approximately 55% to 70% of all NENs. The incidence rate of neuroendocrine neoplasms from gastrointestinal tract and pancreas is about 5.25/100000, which is the second common tumor of gastrointestinal tract. In China, the ratio of incidence rate and prevalence of neuroendocrine neoplasms is estimated to be 4.4, lower than 7.4 in the United States. In 2018, there were 19000 newly diagnosed cases of neuroendocrine neoplasms in the United States. It is noteworthy that compared with other tumors, the survival period of patients with neuroendocrine neoplasms is relatively long. Therefore, although the incidence rate of neuroendocrine neoplasms is relatively low, the patient population is relatively large. In addition, it is estimated that there were approximately 141000 neuroendocrine neoplasm patients in the United States in 2018, of which over 90%, or 132000 patients, were non pancreatic neuroendocrine neoplasm patients. In China, there were approximately 67600 newly diagnosed cases of neuroendocrine neoplasms in 2018. According to China's incidence to prevalence ratio, there may be as many as 300000 patients with neuroendocrine neoplasms in China. It is estimated that about 80% of patients with neuroendocrine neoplasms in China are non pancreatic neuroendocrine neoplasm patients. Octreotide and Lancreotide, which belong to Somatostatin Analogues SSAs, can alleviate symptoms such as flushing and diarrhea caused by carcinoid syndrome and have been widely used in clinical practice. In a phase III clinical study comparing long-acting octreotide LAR with placebo in the treatment of 85 cases of metastatic colorectal cancer NENs (PROMID), octreotide LAR significantly prolonged the time to disease progression (TTP) in patients: Octreotide LAR group at 14.3 months and placebo group at 6 months (p=0.000072). A systematic analysis report shows that after combination therapy with long-acting octreotide and other therapies (including everolimus, peptide receptor radionuclide therapy, bevacizumab, interferon, etc.), 85% of patients' diseases were controlled, with PFS ranging from 15 months to 16.4 months and OS ranging from 25 months to 61.9 months. SSAs are well tolerated drugs with few side effects, usually mild, and do not require discontinuation[5]. The incidence rate of pancreatic neuroendocrine neoplasms (pNENs) is increasing year by year. According to the statistical results of the Surveillance, Epidemiology, and End Results (SEER) database, the incidence rate of pNENs increased from 0.27/100000 to 1/100000 from 2000 to 2016, with a median overall survival time of 68 months, and the 5-year overall survival rates (OS) of localized, locally advanced, and metastatic pNENs were 83%, 67%, and 28% respectively. pNENs are gradually attracting attention and importance from the medical community. The existing therapeutic drugs for neuroendocrine neoplasms include growth hormone inhibitors, recombinant human interferon injections, chemotherapy drugs, and molecular targeted drugs. Although these drugs can to some extent prolong patients' PFS, there is a common problem of low objective response rates. In recent years, sunitinib and everolimus have been approved for targeted therapy in patients with pancreatic neuroendocrine tumors, but their clinical efficacy is still limited. The study from Panzuto et al. showed that the median PFS for first-line treatment of advanced well differentiated pancreatic neuroendocrine neoplasms was 13.9 months, with an ORR of 14.9%. When imaging progression occurred and second-line treatment was adopted, the median PFS after second-line treatment was 15 months, with an ORR of only 5.5%. There is currently no effective treatment for patients with disease progression or drug resistance after existing treatments. Therefore, there is a huge clinical demand for the treatment of pancreatic neuroendocrine neoplasm patients both domestically and globally, and effective drugs are urgently needed to benefit the vast number of patients. Our previous research found that tumor signaling pathways are significantly affected in pancreatic neuroendocrine neoplasms and liver metastasis through KEGG pathway analysis. EGFR tyrosine kinase inhibitor resistance and transcriptional dysregulation in tumors are unique to liver metastasis; Meanwhile, GO biological process analysis emphasizes signaling pathways closely related to tyrosine phosphorylation, DNA repair, and cell cycle regulation. Xiao et al. found that RNA seq was used to enrich epidermal growth factor receptor (EGFR) in high glycosylated pancreatic neuroendocrine neoplasms. Immunohistochemical staining revealed that 21.2% of pancreatic neuroendocrine tumors expressed EGFR, which was associated with low overall survival rate (P=0.020). Therefore, Xiao et al. believe that EGFR may be a potential therapeutic target for pancreatic neuroendocrine neoplasms. This is consistent with our previous findings that the EGFR signaling pathway plays an important role in pancreatic neuroendocrine neoplasms with liver metastasis. Due to the heterogeneity and complexity of tumors, the efficacy of monotherapy or blocking a single signaling pathway may be limited. The existing targeted anti-tumor drugs block tumor angiogenesis by inhibiting vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF). Colony stimulating factor 1 receptor (CSF1R) is an important signaling pathway associated with the survival and function of tumor associated macrophages (TAMs). Inhibiting CSF1R can regulate the activity of macrophages , improve the immune microenvironment, promote immune response in the body, and activate immune function. Sofantinib is a novel oral tyrosine kinase inhibitor that exerts dual effects of anti angiogenesis and immune regulation by targeting vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR1), and colony-stimulating factor 1 receptor (CSF1R) kinases, resulting in synergistic anti-tumor activity. In December 2020 and June 2021, sorafenib was approved in China as a monotherapy for unresectable locally advanced or metastatic, well differentiated extrapancreatic and pancreatic neuroendocrine neoplasms. However, in a multicenter, single blind, open label, phase Ib/II clinical trial, the objective response rate for pancreatic neuroendocrine tumor patients was only 19%, and there is no effective treatment for patients with disease progression or drug resistance after existing treatment regimens. Therefore, there is an urgent need to seek new treatment methods to improve the therapeutic effect of pancreatic neuroendocrine neoplasms. There is a study showing that dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor pathways may delay therapeutic resistance in advanced non-small cell lung cancer (NSCLC). Bevacizumab plus erlotinib significantly improved PFS in patients with untreated metastatic EGFR-mutated NSCLC. Based on previous research results and relevant literature reports, we speculate that the combination of sorafenib and EGFR inhibitors gefitinib may improve the treatment efficacy of patients.

Arms

: experimental group

This study is a single arm design, with only one experimental group set up. Medication plan and cycle: oral administration. Sorafenib: once a day, 250mg each time. Gefitinib: once a day, 250mg each time. Every 4 weeks is a treatment cycle.

Interventions

Drug: - sorafenib, gefitinib

Sofantinib: 250mg, QD, oral; Gefitinib: 250mg, QD, oral.